Balanced Outlook on BMY: Positive Mezigdomide Phase III Data Support CELMoD Platform, but Long-Term Execution Risks Warrant Hold Rating

William Blair analyst Matt Phipps has maintained their neutral stance on BMY stock, giving a Hold rating on March 6.

Matt Phipps has given his Hold rating due to a combination of factors tied to both encouraging data and remaining execution risk. He views the positive interim Phase III SUCCESSOR-2 results for mezigdomide in relapsed or refractory multiple myeloma as reinforcing the long-term promise of the CELMoD platform, especially given the meaningful benefit in progression-free survival versus the existing Kd regimen.

At the same time, he underscores that the broader investment thesis still hinges on future pivotal readouts and successful franchise transitions that are several years away. In particular, he points to the importance of the head-to-head SUCCESSOR-1 trial against Pomalyst and later-stage CELMoD and lymphoma studies, suggesting that while momentum is building, the timeline and residual clinical and regulatory uncertainties justify a balanced, wait-and-see stance on BMY shares.

In another report released on March 6, Citi also maintained a Hold rating on the stock with a $64.00 price target.